Does ADMA cause endothelial dysfunction?
Asymmetric dimethylarginine (ADMA) is an endogenous and competitive inhibitor of nitric oxide synthase. Plasma levels of this inhibitor are elevated in patients with atherosclerosis and in those with risk factors for atherosclerosis. In these patients, plasma ADMA levels are correlated with the severity of endothelial dysfunction and atherosclerosis. By inhibiting the production of nitric oxide, ADMA may impair blood flow, accelerate atherogenesis, and interfere with angiogenesis. ADMA may be a novel risk factor for vascular disease.
Cooke
J P
JP
Division of Cardiovascular Medicine, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA 94305-5406, USA. john.cooke@stanford.edu
D000581:Amidohydrolases; D001120:Arginine / Q000031:analogs & derivatives / Q000378:metabolism*; D001161:Arteriosclerosis / Q000097:blood / Q000201:enzymology / Q000209:etiology*; D004730:Endothelium, Vascular / Q000201:enzymology / Q000378:metabolism*; D006706:Homeostasis; D006801:Humans; D006867:Hydrolases / Q000378:metabolism; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors
D009569:Nitric Oxide; C024917:symmetric dimethylarginine; D001120:Arginine; D019001:Nitric Oxide Synthase; D006867:Hydrolases; D000581:Amidohydrolases; C059999:dimethylargininase